フラグメント抗体の市場規模、シェア、動向分析レポート：特異性別（モノクローナル抗体、ポリクローナル抗体）、タイプ別、療法別、用途別、地域別、セグメント別予測、2022年～2030年

フラグメント抗体の市場成長・動向

Grand View Research, Inc.の新しいレポートによると、世界のフラグメント抗体市場規模は2030年までに113億6000万米ドルに達し、2022年から2030年までCAGR5.9％で拡大すると予測されています。高齢者人口の増加や社会的行動の変化により、世界中で慢性疾患が着実に増加しています。都市化の進展により中間層が増加し、人々はより座りがちで不健康なライフスタイルを送るようになり、その結果、糖尿病などの疾病が増加することになりました。新興市場は、人口の大幅な増加により、最大の患者負担を抱えることになると予想されます。

さらに、主要な市場参加者による投資の拡大が業界の成長に寄与しています。例えば、2020年6月、バンダービルト大学医療センターは、アストラゼネカと協力し、同社のコロナウイルス中和抗体をCOVID-19の治療および予防のための可能な併用療法として臨床開発に進ませました。これらの要因は、今後数年間、市場を牽引するものと思われます。

抗体は、分子やタンパク質の検出のための重要なツールです。ほとんどのイムノアッセイアプリケーションでは全抗体が望ましいとはいえ、一部の実験ではF（ab'）2やFabなどの抗体断片によってのみ性能が向上します。モノクローナル抗体は、様々な癌の治療薬として承認されている重要な治療薬の一種です。すでに80以上の抗体が様々な疾患への適応で承認されており、これらの抗体はバイオ医薬品の中で最大のクラスです。より小型で抗原結合性の高いフラグメント抗体のイントロダクションは速いペースで成長しており、業界にプラスの影響を与えています。

また、フラグメント抗体は、製造・精製コストが低いため、全鎖抗体よりも好まれると予想されています。特定の疾患の治療にフラグメント抗体を使用することは、厳格なICD-10規則によって制約を受ける可能性があります。しかし、重篤な疾患に対するフラグメント抗体の臨床開発における新たな進歩は、大きな市場成長の機会を提供する可能性があります。

フラグメント抗体市場レポートハイライト

特異性別では、モノクローナル抗体が、いくつかの形態の悪性腫瘍の治療において推奨される重要な治療薬クラスと考えられているため、2021年に最大のシェアを占めました。

タイプ別では、scFvセグメントが今後数年間で最も速い成長を遂げると予想されます。scFvは、多価性、異種生産性、低分子量、多量体など、親mAbを上回るいくつかの利点を備えています。

治療法別では、モノクローナル抗体分野が2021年の市場をリードしました。ラニビズマブ（ルセンティス）は、糖尿病性黄斑浮腫、血管新生（湿性）加齢黄斑変性（AMD）などによる視覚障害の治療に用いられるため、2021年に最大の収益シェアを獲得しました。

用途別では、世界のがん罹患率の上昇に伴い、治療目的でのフラグメント抗体の採用が増加していることから、がん分野が予測期間中に最も速い成長を示すと予想されます。

2021年には、免疫不全疾患の増加により、研究目的のフラグメント抗体の需要が増加している北米が市場を独占しました。

アジア太平洋地域は、バイオテクノロジーや製薬研究への民間および公的パートナーシップによる投資が増加していることから、将来的に大きく成長すると予想されています。このため、フラグメント抗体の採用に拍車がかかっています。

目次

第1章 エグゼクティブサマリー

• 市場のスナップショット
• 競合環境
• セグメントの見通し

第2章 調査手法

• 情報調達
• 情報またはデータ分析
• 市場の策定と検証

第3章 フラグメント抗体市場の変数、動向、範囲

• 親市場分析
• 市場力学
  • 市場促進要因分析
    • 感染症および慢性疾患の有病率の増加
    • フラグメント抗体は、他の選択肢よりも優先されます
    • 製薬およびバイオテクノロジー調査への官民投資の増加
  • 市場抑制分析
    • フラグメント抗体の精製における障害

第4章 フラグメント抗体市場：セグメント分析、特異性別、2018年から2030年（100万米ドル）

• 定義と範囲
• 世界のフラグメント抗体市場、特異性別、2018年から2030年（100万米ドル）
• 市場規模と予測、トレンド分析、2018年から2030年までUSD Million Million
  • モノクローナル抗体
  • ポリクローナル抗体

第5章 フラグメント抗体市場：セグメント分析、タイプ別、2018年から2030年（100万米ドル）

• 定義と範囲
• 世界のフラグメント抗体市場、タイプ別、2018年から2030年（100万米ドル）
• 市場規模と予測、トレンド分析、2018年から2030年
  • 素晴らしい
  • scFv
  • sdAb
  • その他

第6章 フラグメント抗体市場：セグメント分析、治療別、2018年から2030年（100万米ドル）

• 定義と範囲
• 世界のフラグメント抗体市場、治療別、2018年から2030年（100万米ドル）
• 市場規模と予測、トレンド分析、2018年から2030年（USD Million）
  • モノクローナル抗体
  • プラックスバインド（イダルシズマブ）
  • ラニビズマブ（ルセンティス）
  • セルトリズマブペゴル（シムジア）
  • ヨウ素（1311）メツキシマブ/リカルチン
  • Beovu（brolucizumab-dbl）
  • Cablivi（caplacizumab-yhdp）
  • ブリナツモマブ/ブリンサイト
  • パブ
  • クロファブ
  • アナビップ
  • アナスコープ
  • ボツリヌス症抗毒素七価（HBAT）
  • デジバインド
  • デジファブ
  • パイプライン
  • AFM13
  • HPN-424
  • MGD007
  • テボテリマブ（MGD013）
  • ベントラシマブ（PB2452）
  • フロテツズマブ（MGD006）
  • AK104
  • オゾラリズマブ
  • ソネロキマブ（ALX0761）

第7章 フラグメント抗体市場：セグメント分析、アプリケーション別、2018年から2030年（100万米ドル）

• 定義と範囲
• アプリケーション別の世界のフラグメント抗体市場、2018年から2030年（100万米ドル）
• 市場規模と予測、トレンド分析、2018年から2030年（USD Million）
  • 癌
  • 免疫不全
  • その他

第8章 フラグメント抗体市場：地域別市場分析、2018年から2030年（100万米ドル）

• 定義と範囲
• 地域市場シェア分析、2021年と2030年
• 地域市場ダッシュボード
• 地域市場：主なプレーヤー
• 市場規模、予測、トレンド分析、2018年から2030年
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • ロシア
• アジア太平洋地域
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国
  • シンガポール
• ラテンアメリカ
  • メキシコ
  • ブラジル
  • アルゼンチン
• 中東とアフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第9章 競合情勢

• 戦略的枠組み
• 市場参加の分類
• 企業プロファイル
  • Pfizer Inc
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Sanofi
    • 会社概要
    • アルビンクス
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Novartis AG
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Genentech, Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • AbbVie Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Bristol-Myers Squibb Company
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Johnson & Johnson Services, Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Lilly
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ

List of Tables

• Table 1 Global Antibody Fragments Market, By Region, 2018 - 2030 (USD Million)
• Table 2 Global Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 3 Global Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 4 Global Antibody Fragments Market, By Therapy 2018 - 2030 (USD Million)
• Table 5 Global Antibody Fragments Market, By Application 2018 - 2030 (USD Million)
• Table 6 North America Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 7 North America Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 8 North America Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
• Table 9 North America Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
• Table 10 U.S. Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 11 U.S. Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 12 U.S. Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
• Table 13 U.S. Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
• Table 14 Canada Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 15 Canada Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 16 Canada Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
• Table 17 Canada Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
• Table 18 Europe Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 19 Europe Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 20 Europe Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
• Table 21 Europe Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
• Table 22 U.K. Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 23 U.K. Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 24 U.K. Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
• Table 25 U.K. Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
• Table 26 Germany Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 27 Germany Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 28 Germany Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
• Table 29 Germany Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
• Table 30 France Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 31 France Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 32 France Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
• Table 33 France Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
• Table 34 Italy Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 35 Italy Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 36 Italy Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
• Table 37 Italy Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
• Table 38 Spain Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 39 Spain Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 40 Spain Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
• Table 41 Spain Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
• Table 42 Russia Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 43 Russia Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 44 Russia Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
• Table 46 Russia Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
• Table 47 Asia Pacific Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
• Table 51 Japan Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 52 Japan Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 53 Japan Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
• Table 54 Japan Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
• Table 55 China Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 56 China Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 57 China Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
• Table 58 China Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
• Table 59 India Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 60 India Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 61 India Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
• Table 62 India Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
• Table 63 Australia Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 64 Australia Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 65 Australia Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
• Table 66 Australia Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
• Table 67 South Korea Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 68 South Korea Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 69 South Korea Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
• Table 70 South Korea Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
• Table 71 Singapore Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 72 Singapore Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 73 Singapore Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
• Table 74 Singapore Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
• Table 75 Latin America Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 76 Latin America Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 77 Latin America Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
• Table 78 Latin America Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
• Table 79 Brazil Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 80 Brazil Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 81 Brazil Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
• Table 82 Brazil Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
• Table 83 Mexico Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 84 Mexico Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 85 Mexico Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
• Table 86 Mexico Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
• Table 87 Argentina Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 88 Argentina Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 89 Argentina Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
• Table 90 Argentina Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
• Table 91 Middle East & Africa Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 92 Middle East & Africa Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 93 Middle East & Africa Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
• Table 94 Middle East & Africa Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
• Table 95 South Africa Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 96 South Africa Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 97 South Africa Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
• Table 98 South Africa Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
• Table 99 Saudi Arabia Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 100 Saudi Arabia Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 101 Saudi Arabia Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
• Table 102 Saudi Arabia Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
• Table 103 UAE Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
• Table 104 UAE Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
• Table 105 UAE Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
• Table 106 UAE Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value chain-based sizing & forecasting
• Fig. 6 Market formulation & validation
• Fig. 7 Antibody fragments market segmentation
• Fig. 8 Market driver relevance analysis (Current & future impact)
• Fig. 9 Market restraint relevance analysis (Current & future impact)
• Fig. 10 Market challenge relevance analysis (Current & future impact)
• Fig. 11 Penetration & growth prospect mapping
• Fig. 12 SWOT analysis, by factor (political & legal, economic and technological)
• Fig. 13 Porter's Five Forces analysis
• Fig. 14 Market penetration vs growth prospect mapping
• Fig. 15 Antibody fragments market: Specificity outlook and key takeaways
• Fig. 16 Antibody fragments market: Specificity movement analysis
• Fig. 17 Monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 18 Polyclonal antibodies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 19 Antibody fragments market: Type outlook and key takeaways
• Fig. 20 Antibody fragments market: Type movement analysis
• Fig. 21 FAB market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 scFv market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 sdAb market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Antibody fragments market: Therapy outlook and key takeaways
• Fig. 26 Antibody fragments market: Therapy movement analysis
• Fig. 27 Monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 PAB market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 Pipeline market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Antibody fragments market: Application outlook and key takeaways
• Fig. 31 Antibody fragments market: Application movement analysis
• Fig. 32 Cancer market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 Immunodeficiency market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 34 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 35 Regional marketplace: Key takeaways
• Fig. 36 Regional outlook, 2021 & 2030
• Fig. 37 North America antibody fragments market, 2018 - 2030 (USD Million)
• Fig. 38 U.S. antibody fragments market, 2018 - 2030 (USD Million)
• Fig. 39 Canada antibody fragments market, 2018 - 2030 (USD Million)
• Fig. 40 Europe antibody fragments market, 2018 - 2030 (USD Million)
• Fig. 41 U.K. antibody fragments market, 2018 - 2030 (USD Million)
• Fig. 42 Germany antibody fragments market, 2018 - 2030 (USD Million)
• Fig. 43 Italy antibody fragments market, 2018 - 2030 (USD Million)
• Fig. 44 Spain antibody fragments market, 2018 - 2030 (USD Million)
• Fig. 45 France antibody fragments market, 2018 - 2030 (USD Million)
• Fig. 46 Russia antibody fragments market, 2018 - 2030 (USD Million)
• Fig. 47 Asia Pacific antibody fragments market, 2018 - 2030 (USD Million)
• Fig. 48 Japan antibody fragments market, 2018 - 2030 (USD Million)
• Fig. 49 China antibody fragments market, 2018 - 2030 (USD Million)
• Fig. 50 India antibody fragments market, 2018 - 2030 (USD Million)
• Fig. 51 Australia antibody fragments market, 2018 - 2030 (USD Million)
• Fig. 52 South Korea antibody fragments market, 2018 - 2030 (USD Million)
• Fig. 53 Singapore antibody fragments market, 2018 - 2030 (USD Million)
• Fig. 54 Latin America antibody fragments market, 2018 - 2030 (USD Million)
• Fig. 55 Brazil antibody fragments market, 2018 - 2030 (USD Million)
• Fig. 56 Mexico antibody fragments market, 2018 - 2030 (USD Million)
• Fig. 57 Argentina antibody fragments market, 2018 - 2030 (USD Million)
• Fig. 58 MEA antibody fragments market, 2018 - 2030 (USD Million)
• Fig. 59 South Africa antibody fragments market, 2018 - 2030 (USD Million)
• Fig. 60 Saudi Arabia antibody fragments market, 2018 - 2030 (USD Million)
• Fig. 61 UAE antibody fragments market, 2018 - 2030 (USD Million)

Antibody Fragments Market Growth & Trends:

The global antibody fragments market size is expected to reach USD 11.36 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 5.9% from 2022 to 2030. There has been a steady increase in chronic conditions across the globe owing to the increasing geriatric population and societal behavior changes. The expediting urbanization is leading to the growth of the middle class resulting in people adopting a more sedentary and unhealthier lifestyle, in turn, causing an increase in diseases such as diabetes. The emerging markets are predicted to hold the largest patient burden owing to the significant population growth.

Furthermore, growing investments by the key market players have contributed to the industry growth. For instance, in June 2020, Vanderbilt University Medical Center collaborated with AstraZeneca to advance the company's coronavirus-neutralizing antibodies into clinical development as a possible combination therapy for the treatment and prevention of COVID-19. These factors would drive the market in the coming years.

Antibodies are an important tool for molecular and protein detection. Even though whole antibodies are preferable for most immunoassay applications, the performance for some experiments is only enhanced by antibody fragments, such as F(ab')2 and Fab. Monoclonal antibodies are a significant class of therapeutic drugs that have received approval to treat various cancers. With more than 80 antibodies already approved for use in various disease indications, these antibodies represent the largest class of biopharmaceuticals. The introduction of smaller, antigen-binding antibody fragments has been growing at a fast pace, which is impacting the industry positively.

Antibody fragments are also anticipated to be preferred over full-chain antibodies due to their lower manufacturing and purification costs. The use of antibody fragments for the treatment of a specific disease may be constrained by strict ICD-10 rules. However, the new advancements in the clinical development of antibody fragments for serious diseases may offer significant market growth opportunities.

Antibody Fragments Market Report Highlights:

• By specificity, monoclonal antibodies held the largest share in 2021 as they are considered a significant class of therapeutic agents recommended in the therapy of several forms of malignancies

• Based on type, the scFv segment is anticipated to witness the fastest growth in the coming years. They provide several advantages such as multivalency, heterologous production, low molecular weight, and multimeric form over the parent mAb

• By therapy, the monoclonal antibodies segment led the market in 2021. Ranibizumab (Lucentis) captured the largest revenue share in 2021 as these are used for the treatment of visual impairment due to diabetic macular edema, neovascular (wet) age-related macular degeneration (AMD), and others

• By application, the cancer segment is expected to witness the fastest growth over the forecast period owing to the increasing prevalence of cancer globally, which is resulting in the increasing adoption of antibody fragments for therapeutic purposes

• North America dominated the market in 2021 owing to the increasing prevalence of immunodeficiency diseases, which has led to the increasing demand for antibody fragments for research purposes

• Asia Pacific is expected to grow considerably in the future owing to increasing private and public partnership investments in biotech and pharmaceutical research. This has fueled the adoption of antibody fragments

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Competition Milieu
• 1.3. Segment Outlook

Chapter 2. Research Methodology

• 2.1. Information Procurement
• 2.2. Information or Data Analysis
• 2.3. Market Formulation & Validation

Chapter 3. Antibody Fragments Market Variables, Trends & Scope

• 3.1. Parent Market Analysis
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of infectious and chronic diseases
    • 3.2.1.2. Antibody fragments are preferred over other alternatives
    • 3.2.1.3. Increasing public-private investments for pharma and biotech research
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Obstacles in the purification of antibody fragments

Chapter 4. Antibody Fragments Market: Segment Analysis, By Specificity, 2018 - 2030 (USD Million)

• 4.1. Definitions & Scope
• 4.2. Global Antibody Fragments Market, By Specificity, 2018 to 2030 (USD Million)
• 4.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 USD Million
  • 4.3.1. Monoclonal Antibodies
    • 4.3.1.1. Global Antibody Fragments Market, Monoclonal Antibodies, 2018 to 2030 (USD Million)
  • 4.3.2. Polyclonal Antibodies
    • 4.3.2.1. Global Antibody Fragments Market, Monoclonal Antibodies, 2018 to 2030 (USD Million)

Chapter 5. Antibody Fragments Market: Segment Analysis, By Type, 2018 - 2030 (USD Million)

• 5.1. Definitions & Scope
• 5.2. Global Antibody Fragments Market, By Type, 2018 to 2030 (USD Million)
• 5.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 5.3.1. FAB
    • 5.3.1.1. Global Antibody Fragments Market, FAB, 2018 to 2030 (USD Million)
  • 5.3.2. scFv
    • 5.3.2.1. Global Antibody Fragments Market,scFv, 2018 to 2030 (USD Million)
  • 5.3.3. sdAb
    • 5.3.3.1. Global Antibody Fragments Market, sdAb, 2018 to 2030 (USD Million)
  • 5.3.4. Others
    • 5.3.4.1. Global Antibody Fragments Market, others, 2018 to 2030 (USD Million)

Chapter 6. Antibody Fragments Market: Segment Analysis, By Therapy, 2018 - 2030 (USD Million)

• 6.1. Definitions & Scope
• 6.2. Global Antibody Fragments Market, By Therapy, 2018 to 2030 (USD Million)
• 6.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
  • 6.3.1. Monoclonal Antibodies
  • 6.3.2. Praxbind (idarucizumab)
    • 6.3.2.1. Global Antibody Fragments Market, Praxbind (idarucizumab), 2018 to 2030 (USD Million)
  • 6.3.3. Ranibizumab (Lucentis)
    • 6.3.3.1. Global Antibody Fragments Market, Ranibizumab (Lucentis), 2018 to 2030 (USD Million)
  • 6.3.4. Certolizumab pegol (Cimzia)
    • 6.3.4.1. Global Antibody Fragments Market, Certolizumab pegol (Cimzia), 2018 to 2030 (USD Million)
  • 6.3.5. Iodine (1311) Metuximab/ Licartin
    • 6.3.5.1. Global Antibody Fragments Market, Iodine (1311) Metuximab/ Licartin, 2018 to 2030 (USD Million)
  • 6.3.6. Beovu (brolucizumab-dbll)
    • 6.3.6.1. Global Antibody Fragments Market, Beovu (brolucizumab-dbll), 2018 to 2030 (USD Million)
  • 6.3.7. Cablivi (caplacizumab-yhdp)
    • 6.3.7.1. Global Antibody Fragments Market, Cablivi (caplacizumab-yhdp), 2018 to 2030 (USD Million)
  • 6.3.8. Blinatumomab/ Blincyto
    • 6.3.8.1. Global Antibody Fragments Market, Blinatumomab/ Blincyto, 2018 to 2030 (USD Million)
  • 6.3.9. PAB
  • 6.3.10. CroFab
    • 6.3.10.1. Global Antibody Fragments Market, CroFab, 2018 to 2030 (USD Million)
  • 6.3.11. Anavip
    • 6.3.11.1. Global Antibody Fragments Market, Anavip, 2018 to 2030 (USD Million)
  • 6.3.12. Anascorp
    • 6.3.12.1. Global Antibody Fragments Market, Anascorp, 2018 to 2030 (USD Million)
  • 6.3.13. Botulism Antitoxin Heptavalent (HBAT)
    • 6.3.13.1. Global Antibody Fragments Market, Botulism Antitoxin Heptavalent (HBAT), 2018 to 2030 (USD Million)
  • 6.3.14. Digibind
    • 6.3.14.1. Global Antibody Fragments Market, Digibind, 2018 to 2030 (USD Million)
  • 6.3.15. DigiFab
    • 6.3.15.1. Global Antibody Fragments Market, DigiFab, 2018 to 2030 (USD Million)
  • 6.3.16. Pipeline
  • 6.3.17. AFM13
    • 6.3.17.1. Global Antibody Fragments Market, AFM13, 2018 to 2030 (USD Million)
  • 6.3.18. HPN-424
    • 6.3.18.1. Global Antibody Fragments Market, HPN-424, 2018 to 2030 (USD Million)
  • 6.3.19. MGD007
    • 6.3.19.1. Global Antibody Fragments Market, MGD007, 2018 to 2030 (USD Million)
  • 6.3.20. Tebotelimab (MGD013)
    • 6.3.20.1. Global Antibody Fragments Market, Tebotelimab (MGD013), 2018 to 2030 (USD Million)
  • 6.3.21. Bentracimab (PB2452)
    • 6.3.21.1. Global Antibody Fragments Market, Bentracimab (PB2452), 2018 to 2030 (USD Million)
  • 6.3.22. Flotetuzumab (MGD006)
    • 6.3.22.1. Global Antibody Fragments Market, Flotetuzumab (MGD006), 2018 to 2030 (USD Million)
  • 6.3.23. AK104
    • 6.3.23.1. Global Antibody Fragments Market, AK104, 2018 to 2030 (USD Million)
  • 6.3.24. Ozoralizumab
    • 6.3.24.1. Global Antibody Fragments Market, Ozoralizumab, 2018 to 2030 (USD Million)
  • 6.3.25. Sonelokimab (ALX0761)
    • 6.3.25.1. Global Antibody Fragments Market, Sonelokimab (ALX0761), 2018 to 2030 (USD Million)

Chapter 7. Antibody Fragments Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)

• 7.1. Definitions & Scope
• 7.2. Global Antibody Fragments Market, By Application, 2018 to 2030 (USD Million)
• 7.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
  • 7.3.1. Cancer
    • 7.3.1.1. Global Antibody Fragments Market, Cancer, 2018 to 2030 (USD Million)
  • 7.3.2. Immunodeficiency
    • 7.3.2.1. Global Antibody Fragments Market, Immunodeficiency, 2018 to 2030 (USD Million)
  • 7.3.3. Others
    • 7.3.3.1. Global Antibody Fragments Market, Others, 2018 to 2030 (USD Million)

Chapter 8. Antibody Fragments Market: Regional Market Analysis, By Region, 2018 - 2030 (USD Million)

• 8.1. Definitions & Scope
• 8.2. Regional market share analysis, 2021&2030
• 8.3. Regional Market Dashboard
• 8.4. Regional Market: Key Players
• 8.5. Market Size, & Forecasts, and Trend Analysis, 2018 to 2030
• 8.6. North America
  • 8.6.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
  • 8.6.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
  • 8.6.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
  • 8.6.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.6.5. U.S.
    • 8.6.5.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.6.5.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.6.5.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.6.5.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.6.6. Canada
    • 8.6.6.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.6.6.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.6.6.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.6.6.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
• 8.7. Europe
  • 8.7.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
  • 8.7.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
  • 8.7.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
  • 8.7.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.7.5. Germany
    • 8.7.5.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.7.5.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.7.5.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.7.5.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.7.6. U.K.
    • 8.7.6.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.7.6.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.7.6.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.7.6.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.7.7. France
    • 8.7.7.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.7.7.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.7.7.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.7.7.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.7.8. Italy
    • 8.7.8.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.7.8.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.7.8.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.7.8.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.7.9. Spain
    • 8.7.9.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.7.9.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.7.9.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.7.9.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.7.10. Russia
    • 8.7.10.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.7.10.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.7.10.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.7.10.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
• 8.8. Asia Pacific
  • 8.8.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
  • 8.8.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
  • 8.8.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
  • 8.8.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.8.5. China
    • 8.8.5.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.8.5.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.8.5.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.8.5.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.8.6. Japan
    • 8.8.6.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.8.6.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.8.6.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.8.6.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.8.7. India
    • 8.8.7.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.8.7.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.8.7.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.8.7.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.8.8. Australia
    • 8.8.8.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.8.8.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.8.8.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.8.8.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.8.9. South Korea
    • 8.8.9.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.8.9.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.8.9.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.8.9.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.8.10. Singapore
    • 8.8.10.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.8.10.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.8.10.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.8.10.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
• 8.9. Latin America
  • 8.9.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
  • 8.9.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
  • 8.9.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
  • 8.9.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.9.5. Mexico
    • 8.9.5.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.9.5.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.9.5.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.9.5.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.9.6. Brazil
    • 8.9.6.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.9.6.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.9.6.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.9.6.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.9.7. Argentina
    • 8.9.7.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.9.7.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.9.7.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.9.7.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
• 8.10. Middle East & Africa
  • 8.10.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
  • 8.10.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
  • 8.10.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
  • 8.10.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.10.5. South Africa
    • 8.10.5.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.10.5.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.10.5.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.10.5.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.10.6. Saudi Arabia
    • 8.10.6.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.10.6.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.10.6.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.10.6.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.10.7. UAE
    • 8.10.7.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.10.7.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.10.7.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.10.7.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Strategy Framework
• 9.2. Market Participation Categorization
• 9.3. Company Profile
  • 9.3.1. Pfizer Inc
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Product Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Sanofi
    • 9.3.2.1. Company Overview
    • 9.3.2.1.1. Albynx
    • 9.3.2.1.1.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Product Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Novartis AG
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Product Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Genentech, Inc.
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Product Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. AbbVie Inc.
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Product Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Bristol-Myers Squibb Company
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Product Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Johnson & Johnson Services, Inc.
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Product Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Lilly
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Product Benchmarking
    • 9.3.8.4. Strategic Initiatives